Company Filing History:
2 out of 8,396 
2 out of 1,210 
1 out of 444 
Years Active: 2022-2024
Title: Innovations in Cancer Treatment: The Contributions of Nathan D. Mathewson
Introduction
Nathan D. Mathewson is a notable inventor based in Boston, MA, who has made significant strides in the field of cancer treatment. With two patented inventions, his work focuses on targeting specific pathways involved in cancer progression, offering new hope for effective therapies.
Latest Patents
Mathewson's most recent patents are centered around groundbreaking methodologies for treating cancer by targeting the CLEC2D-KLRB1 pathway. One patent elaborates on methods and compositions designed to treat cancer in subjects particularly affected by glioblastoma multiforme (GBM). The KLRB1, or CD161, is a C-type lectin protein that binds to CLEC2D, which has been identified as a critical factor inhibiting the cytotoxic functions of natural killer (NK) cells and cytokine secretion. His innovative approach includes the administration of agents that can block this interaction, such as monoclonal antibodies that selectively bind to KLRB1 or CLEC2D, potentially enhancing anti-tumor immunity.
Career Highlights
Nathan Mathewson has held influential positions at renowned institutions, such as the Massachusetts Institute of Technology (MIT) and Dana-Farber Cancer Institute Inc. His work at these prestigious organizations underscores his commitment to advancing cancer research and treatment methodologies through innovative solutions.
Collaborations
Throughout his career, Mathewson has collaborated with eminent colleagues, including Kai W. Wucherpfennig and Karl Dane Wittrup. These partnerships have fostered a collaborative environment that enhances research outcomes and accelerates the development of effective cancer therapies.
Conclusion
Nathan D. Mathewson's contributions to the field of cancer treatment through his patents reflect his dedication to improving patient outcomes. His research into the CLEC2D-KLRB1 pathway holds promise for developing new therapeutic strategies that could change the landscape of cancer treatment in the future.